Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma is a lethal cancer with fewer than 7% of patients surviving past 5 years. T-cell immunity has been linked to the exceptional outcome of the few long-term survivors, yet the relevant antigens remain unknown. Here we use genetic, immunohistochemical and transcriptional immunoprofiling, computational biophysics, and functional assays to identify T-cell antigens in long-term survivors of pancreatic cancer. Using whole-exome sequencing and in silico neoantigen prediction, we found that tumours with both the highest neoantigen number and the most abundant CD8+ T-cell infiltrates, but neither alone, stratified patients with the longest survival. Investigating the specific neoantigen qualities promoting T-cell activation in long-term survivors, we discovered that these individuals were enriched in neoantigen qualities defined by a fitness model, and neoantigens in the tumour antigen MUC16 (also known as CA125). A neoantigen quality fitness model conferring greater immunogenicity to neoantigens with differential presentation and homology to infectious disease-derived peptides identified long-term survivors in two independent datasets, whereas a neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did not. We detected intratumoural and lasting circulating T-cell reactivity to both high-quality and MUC16 neoantigens in long-term survivors of pancreatic cancer, including clones with specificity to both high-quality neoantigens and predicted cross-reactive microbial epitopes, consistent with neoantigen molecular mimicry. Notably, we observed selective loss of high-quality and MUC16 neoantigenic clones on metastatic progression, suggesting neoantigen immunoediting. Our results identify neoantigens with unique qualities as T-cell targets in pancreatic ductal adenocarcinoma. More broadly, we identify neoantigen quality as a biomarker for immunogenic tumours that may guide the application of immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In rare patients with localized PDAC who are long-term survivors, bacteria can translocate from the intestine into the tumour and control anti-tumour immune activation11,12.”
From Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer (2023) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, the gut microbiota can indirectly increase the immunogenicity of tumor cells by providing tumor cross-antigens to promote the efficacy of ICI [50, 68, 69].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PDAC tumors from long term survivors have high quantity and quality of neoantigens, and stronger infiltration and activation of CD8+ T cells”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These data suggest that microbial host factors, independent of the genomic composition of the tumor, may determine tumor behavior and patient outcomes.”
From Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes (2019) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Significantly, the aggressive progression of PDAC, characterized by immune evasion and therapeutic resistance, is heavily influenced by the TME (Balachandran et al., 2017).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Balachandran et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The Ensembl Variant Effect Predictor
McLaren, W., Gil, L., Hunt, S. E., Riat, H. S., Ritchie, G. R. S., Thormann, A., Flicek, P., & Cunningham, F. (2016) · Genome Biology · doi:10.1186/s13059-016-0974-4 · Cited by 8,099
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 829
Cited by
Items 201–300 of 1,001
Pancreatic cancer–restricted cryptic antigens are targets for T cell recognition
Ely, Z. A., Kulstad, Z. J., Günaydın, G., Addepalli, S., Verzani, E. K., Casarrubios, M., Clauser, K. R., Wang, X., Lippincott, I. E., Louvet, C., et al. (2025) · Science · doi:10.1126/science.adk3487 · Cited by 101
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 114
Immunotherapy in hepatocellular carcinoma
Buonaguro, L., Mauriello, A., Cavalluzzo, B., Petrizzo, A., & Tagliamonte, M. (2019) · Annals of Hepatology · doi:10.1016/j.aohep.2019.04.003 · Cited by 66
Burrack, A. L., Spartz, E. J., Raynor, J. F., Wang, I., Olson, M. A., & Stromnes, I. M. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.059 · Cited by 93
Javadrashid, D., Baghbanzadeh, A., Derakhshani, A., Leone, P., Silvestris, N., Racanelli, V., Solimando, A. G., & Baradaran, B. (2021) · Biomedicines · doi:10.3390/biomedicines9040373 · Cited by 105
Chamseddine, A. N., Assi, T., Mir, O., & Chouaïb, S. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107986 · Cited by 94
Holm, J. S., Funt, S. A., Borch, A., Munk, K. K., Bjerregaard, A.-M., Reading, J. L., Maher, C., Regazzi, A., Wong, P., Al-Ahmadie, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29342-0 · Cited by 86
Self-citationCellular determinants and therapeutic implications of inflammation in pancreatic cancer
Stone, M. L., & Beatty, G. L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.012 · Cited by 91
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Wang, Y., Shi, T., Song, X., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.023 · Cited by 84
Facts and Hopes in Immunotherapy of Pancreatic Cancer
Bockorny, B., Grossman, J. E., & Hidalgo, M. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3452 · Cited by 99
Picard, F. S. R., Lutz, V., Brichkina, A. I., Neuhaus, F., Ruckenbrod, T., Hupfer, A., Raifer, H., Klein, M., Bopp, T., Pfefferle, P. I., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327855 · Cited by 94
Nanomedicines for an Enhanced Immunogenic Cell Death-Based In Situ Cancer Vaccination Response
Zhao, C., Wang, C., Shan, W., Wang, Z., Chen, X. S., & Deng, H. (2024) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00771 · Cited by 93
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
“They matched the sequences from CD8 T cells detected in the original tumors (Łuksza et al. 2017, Balachandran et al. 2017).”
BackgroundSelf-citationSystems Immunology: Learning the Rules of the Immune System
Villani, A., Sarkizova, S., & Hacohen, N. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053035 · Cited by 102
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
Peng, S., Zaretsky, J. M., Ng, A. H. C., Chour, W., Bethune, M. T., Choi, J., Hsu, A., Holman, E., Ding, X., Guo, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.106 · Cited by 83
Modeling pancreatic cancer in mice for experimental therapeutics
Mallya, K. B., Gautam, S. K., Aithal, A., Batra, S. K., & Jain, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188554 · Cited by 98
Fitzgerald, A. A., Wang, S., Agarwal, V. R., Davis-Marcisak, E. F., Zuo, A., Jablonski, S. A., Loth, M., Fertig, E. J., MacDougall, J. R., Zhukovsky, E. A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002837 · Cited by 87
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment
Lafaro, K. J., & Melstrom, L. G. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.09.009 · Cited by 89
Ragone, C., Manolio, C., Cavalluzzo, B., Mauriello, A., Tornesello, M. L., Buonaguro, L., Castiglione, F., Vitagliano, L., Iaccarino, E., Ruvo, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002694 · Cited by 86
Knudsen, E. S., Kumarasamy, V., Chung, S., Ruiz, A., Vail, P., Tzetzo, S., Wu, J., Nambiar, R., Sivinski, J., Chauhan, S. S., et al. (2021) · Gut · doi:10.1136/gutjnl-2020-321000 · Cited by 82
Masugi, Y. (2022) · Cancers · doi:10.3390/cancers14133293 · Cited by 102
Tumor microenvironment antigens
Andersen, M. H. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00966-0 · Cited by 89
FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer
Canel, M., Sławińska, A., Lonergan, D. W., Kallor, A. A., Upstill‐Goddard, R., Davidson, C., von Kriegsheim, A., Biankin, A. V., Byron, A., Alfaro, J. A., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327927 · Cited by 95
Cancer Biomarker Discovery for Precision Medicine: New Progress
Zou, J., & Wang, E. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180718164712 · Cited by 81
Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space
Ogishi, M., & Yotsuyanagi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00827 · Cited by 96
The intricate relationship between diabetes, obesity and pancreatic cancer
Paternoster, S., & Falasca, M. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188326 · Cited by 88
The Pancreatic Microbiome is Associated with Carcinogenesis and Worse Prognosis in Males and Smokers
Chakladar, J., Kuo, S. Z., Castaneda, G., Li, W. T., Gnanasekar, A., Yu, M. A., Chang, E. Y., Wang, X. Q., & Ongkeko, W. M. (2020) · Cancers · doi:10.3390/cancers12092672 · Cited by 78
Chen, Z., Zhang, S., Han, N., Jiang, J., Xu, Y., Ma, D., Lu, L., Guo, X., Qiu, M. R., Huang, Q., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.691605 · Cited by 84
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
Sivaram, N., McLaughlin, P. A., Han, H. V., Petrenko, O., Jiang, Y.-P., Ballou, L. M., Pham, K., Liu, C., van der Velden, A. W. M., & Lin, R. Z. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123540 · Cited by 78
Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor
Vitiello, G. A., Bowler, T. G., Liu, M., Medina, B. D., Zhang, J. Q., Param, N. J., Loo, J. K., Goldfeder, R. L., Chibon, F., Rossi, F., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci124108 · Cited by 91
Self-citationPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Clinical Impact of Molecular Subtyping of Pancreatic Cancer
Zhou, X., Hu, K., Bailey, P. J., Springfeld, C., Roth, S., Kurilov, R., Brors, B., Gress, T. M., Buchholz, M., An, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.743908 · Cited by 87
Müller, M., Haghnejad, V., Schaefer, M., Gauchotte, G., Caron, B., Peyrin‐Biroulet, L., Bronowicki, J., Neuzillet, C., & Lopez, A. (2022) · Cancers · doi:10.3390/cancers14040995 · Cited by 92
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
Hoyos, D., Zappasodi, R., Schulze, I., Sethna, Z., de Andrade, K. C., Bajorin, D. F., Bandlamudi, C., Callahan, M. K., Funt, S. A., Hadrup, S. R., et al. (2022) · Nature · doi:10.1038/s41586-022-04696-z · Cited by 80
Self-citationEvolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Shaikh, F. Y., Gills, J. J., & Sears, C. L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.076 · Cited by 77
Costa, A. D., Väyrynen, S. A., Chawla, A., Zhang, J., Väyrynen, J. P., Lau, M. C., Williams, H. L., Yuan, C., Morales-Oyarvide, V., Elganainy, D., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1125 · Cited by 82
Self-citationSchischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M., Holly, R., Fuchs, E., Milosevic Feenstra, J. D., Bogner, E., Gisslinger, B., et al. (2019) · Blood · doi:10.1182/blood.2019000519 · Cited by 78
Bassani-Sternberg, M., Digklia, A., Huber, F., Wagner, D., Sempoux, C., Stevenson, B. J., Thierry, A.-C., Michaux, J., Pak, H., Racle, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01832 · Cited by 74
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 86
Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on
Verbeke, C. S., Häberle, L., Lenggenhager, D. M., & Esposito, I. (2018) · Pancreatology · doi:10.1016/j.pan.2018.04.010 · Cited by 76
Tumor B7-H3 (CD276) Expression and Survival in Pancreatic Cancer
Inamura, K., Takazawa, Y., Inoue, Y., Yokouchi, Y., Kobayashi, M., Saiura, A., Shibutani, T., & Ishikawa, Y. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7070172 · Cited by 73
Crawford, H. C., di Magliano, M. P., & Banerjee, S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.042 · Cited by 77
Abe, S., Masuda, A., Matsumoto, T., Inoue, J., Toyama, H., Sakai, A., Kobayashi, T., Tanaka, T., Tsujimae, M., Yamakawa, K., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-023-02069-5 · Cited by 81
Hilmi, M., Delaye, M., Muzzolini, M., Nicolle, R., Cros, J. F., Hammel, P. R., Cardot‐Ruffino, V., & Neuzillet, C. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(23)00207-8 · Cited by 82
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
Frankel, A. E., Deshmukh, S. K., Reddy, A., Lightcap, J., Hayes, M., McClellan, S. B., Singh, S., Rabideau, B. D., Glover, T. G., Roberts, B., et al. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419846379 · Cited by 76
Upadhrasta, S., & Zheng, L. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091472 · Cited by 73
Structural dissimilarity from self drives neoepitope escape from immune tolerance
Devlin, J. R., Alonso, J. A., Ayres, C. M., Keller, G. L. J., Bobisse, S., Kooi, C. W. V., Coukos, G., Gfeller, D., Harari, A., & Baker, B. M. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0610-1 · Cited by 71
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer
Botta, G. P., Kato, S., Patel, H., Fanta, P. T., Lee, S., Okamura, R., & Kurzrock, R. (2021) · JCI Insight · doi:10.1172/jci.insight.150453 · Cited by 79
Carbone, C., Piro, G., Agostini, A., Delfino, P., Sanctis, F. D., Nasca, V., Spallotta, F., Sette, C., Martini, M., Ugel, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002876 · Cited by 72
Control of Dendritic Cell Function Within the Tumour Microenvironment
Hari‐Gupta, Y., Khanom, A., & Acton, S. E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.733800 · Cited by 78
Chen, J., Song, Y., Miao, F., Chen, G., Zhu, Y., Wu, N., Pang, L., Chen, Z., & Chen, X. (2021) · Cancer Science · doi:10.1111/cas.15033 · Cited by 76
The tumour microenvironment in pancreatic cancer — new clinical challenges, but more opportunities
Kung, H., Zheng, K., Zimmerman, J. W., & Zheng, L. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01077-z · Cited by 100
Lau, S. P., van Montfoort, N., Kinderman, P., Lukkes, M. M., Klaase, L., van Nimwegen, M., van Gulijk, M., Dumas, J., Mustafa, D. A. M., Lievense, S., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000772 · Cited by 75
Roth, S., Zamzow, K., Gaida, M. M., Heikenwälder, M. F., Tjaden, C., Hinz, U., Bose, P., Michalski, C. W., & Hackert, T. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102714 · Cited by 75
Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer
Mahadevan, K. K., Dyevoich, A. M., Chen, Y., Li, B., Sugimoto, H., Sockwell, A. M., McAndrews, K. M., Sthanam, L. K., Wang, H., Shalapour, S., et al. (2024) · Science · doi:10.1126/science.adh4567 · Cited by 78
Ge, W., Hu, H., Cai, W., Xu, J., Hu, W., Weng, X., Qin, X., Huang, Y., Han, W., Hu, Y., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32775 · Cited by 72
Schmidt, J., Chiffelle, J., Perez, M. A. S., Magnin, M., Bobisse, S., Arnaud, M., Genolet, R., Cesbron, J., Barras, D., Rodrigo, B. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38946-z · Cited by 84
The Landscape of Tumor Fusion Neoantigens: A Pan-Cancer Analysis
Wei, Z., Zhou, C., Zhang, Z., Guan, M., Zhang, C., Liu, Z., & Liu, Q. (2019) · iScience · doi:10.1016/j.isci.2019.10.028 · Cited by 67
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Young, K., Hughes, D. J., Cunningham, D., & Starling, N. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918816281 · Cited by 71
Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor
Min, T., Xie, X., Ren, K., Sun, T., Wang, H., Dang, C., & Zhang, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.884887 · Cited by 76
Broadening oncological boundaries: the intratumoral microbiota
Lu, Y.-Q., Qiao, H., Tan, X.-R., & Liu, N. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.007 · Cited by 66
Improving outcomes of patients with pancreatic cancer
Dreyer, S. B., Beer, P. A., Hingorani, S. R., & Biankin, A. V. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01019-9 · Cited by 81
Zhang, J., Caruso, F. P., Sa, J. K., Justesen, S. F. L., Nam, D., Sims, P. A., Ceccarelli, M., Lasorella, A., & Iavarone, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0369-7 · Cited by 72
Self-citationChen, H., Yang, M., Wang, Q., Song, F., Li, X., & Chen, K. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1608132 · Cited by 88
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Pan, P., & Haggiagi, A. M. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0859-2 · Cited by 67
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 74
Chen, Q., Yin, H., Liu, S., Shoucair, S., Ding, N., Ji, Y., Zhang, J., Wang, D., Kuang, T., Xu, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005798 · Cited by 69
Self-citationThe role of dendritic cells in tumor microenvironments and their uses as therapeutic targets
Kim, C. W., Kim, K.-D., & Lee, H. K. (2021) · BMB Reports · doi:10.5483/bmbrep.2021.54.1.224 · Cited by 62
Hofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
Laethem, J. V., Borbath, I., Prenen, H., Geboes, K., Lambert, A., Mitry, E., Cassier, P. A., Blanc, J., Pilla, L., Feliú, J., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00263-8 · Cited by 67
Mahmood, J., Shukla, H. D., Soman, S., Samanta, S., Singh, P., Kamlapurkar, S., Saeed, A. M., Amin, N. P., & Vujašković, Ž. (2018) · Cancers · doi:10.3390/cancers10120469 · Cited by 68
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 67
Self-citationGrauslund, J. H., Holmström, M. O., Jørgensen, N. G. D., Klausen, U., Weis-Banke, S. E., Fassi, D. E., Schöllkopf, C., Clausen, M. B., Gjerdrum, L. M. R., Breinholt, M. F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.637420 · Cited by 68
Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling
Johansson, A., & Ganß, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.674375 · Cited by 70
Oshi, M., Newman, S., Tokumaru, Y., Yan, L., Matsuyama, R., Endo, I., Katz, M. H. G., & Takabe, K. (2020) · Cancers · doi:10.3390/cancers12102871 · Cited by 71
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Thomas, D., Sagar, S., Liu, X., Lee, H.-R., Grunkemeyer, J. A., Grandgenett, P. M., Caffrey, T. C., O’Connell, K. A., Swanson, B. J., Marcos-Silva, L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.029 · Cited by 68
Tumor-Associated Microbiome: Where Do We Stand?
Oliva, M., Mulet-Margalef, N., Ochoa-de-Olza, M., Napoli, S., Mas-Lloret, J., Laquente, B., Alemany, L., Duell, E. J., Nuciforo, P. G., & Moreno, V. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031446 · Cited by 66
Sources of Cancer Neoantigens beyond Single-Nucleotide Variants
Capietto, A.-H., Hoshyar, R., & Delamarre, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710131 · Cited by 69
Roehle, K., Li, Q., Ventre, K. S., Heid, D., Ali, L. R., Lenehan, P. J., Heckler, M., Crowley, S. J., Stump, C. T., Ro, G., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf5058 · Cited by 65
Seifert, L., Plesca, I., Müller, L., Sommer, U. J., Heiduk, M., von Renesse, J., Digomann, D., Glück, J., Klimová, A., Weitz, J., et al. (2021) · Cancers · doi:10.3390/cancers13061297 · Cited by 65
Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens
Weber, D., Ibn-Salem, J., Sorn, P., Suchan, M., Holtsträter, C., Lahrmann, U., Vogler, I., Schmoldt, K., Lang, F., Schrörs, B., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01247-9 · Cited by 59
The effect of the intratumoral microbiome on tumor occurrence, progression, prognosis and treatment
Gao, F., Yu, B., Rao, B., Sun, Y. H., Yu, J., Wang, D., Cui, G., & Ren, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051987 · Cited by 71
Vonderhaar, E. P., Barnekow, N. S., McAllister, D., McOlash, L., Eid, M. A., Riese, M. J., Tarakanova, V. L., Johnson, B. D., & Dwinell, M. B. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.018 · Cited by 61
“Although most PDA tumors are immune suppressed, the presence of tumor antigen-specific T cells in the tumor and periphery has been linked to long-term PDA survival, demonstrating the importance of generating widespread immunity.(35) Thus, we examined whether the immunestimulating effects of STING agonist were restrict…”
BackgroundPearce, H., Croft, W. D., Nicol, S. M., Margielewska‐Davies, S., Powell, R., Cornall, R. J., Davis, S. J., Marcon, F., Pugh, M., Fennell, É., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0121 · Cited by 66
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 69
Self-citationGut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 58
Cao, C., Yue, S., Lü, A., & Liang, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107321 · Cited by 67
Loveless, I. M., Kemp, S. B., Hartway, K. M., Mitchell, J. T., Wu, Y., Zwernik, S. D., Salas-Escabillas, D. J., Brender, S. M., George, M., Makinwa, Y., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2183 · Cited by 68
MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy
Gautam, S. K., Sushil Kumar, K., Dam, V., Ghersi, D., Jain, M., & Batra, S. K. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101391 · Cited by 67
Microbiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer
Bellone, M., Brevi, A., & Huber, S. (2020) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00064-19 · Cited by 65
The intratumoral microbiome: Characterization methods and functional impact
Heymann, C. J. F., Bard, J.-M., Heymann, M.-F., Heymann, D., & Bobin-Dubigeon, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.009 · Cited by 57
Karamitopoulou, E., Andreou, A., Wenning, A. S., Gloor, B., & Perren, A. A. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.033 · Cited by 64
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 68
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 61
Cancer Immunosurveillance by T Cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2018.08.001 · Cited by 58
RBM10: Structure, functions, and associated diseases
Inoue, A. (2021) · Gene · doi:10.1016/j.gene.2021.145463 · Cited by 62
Liu, Y., Niu, R., Zhang, X., Zhang, B., Chen, X., Guo, J., Song, S., Wang, Y., Zhang, H., & Zhao, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c01518 · Cited by 64
Metadata
- Authors
- Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., Senbabaoglu, Y., Wells, D. K., Cary, C. I. O., Grbovic-Huezo, O., Attiyeh, M., Medina, B., Zhang, J., Loo, J., Saglimbeni, J., Abu-Akeel, M., Zappasodi, R., Riaz, N., Smoragiewicz, M., Kelley, Z. L., Basturk, O., Gönen, M., Levine, A. J., Allen, P. J., Fearon, D. T., Merad, M., Gnjatic, S., Iacobuzio-Donahue, C. A., Wolchok, J. D., DeMatteo, R. P., Chan, T. A., Greenbaum, B. D., Merghoub, T., & Leach, S. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Parker Institute for Cancer Immunotherapy (US)
- Swim Across America (US)
- University of Cambridge (GB)
- Cold Spring Harbor Laboratory (US)
- Corresponding author
- Balachandran, Vinod P.
- ORCID
- Balachandran, Vinod P.
- Łuksza, Marta
- Zhao, Julia N.
- Makarov, Vladimir
- Herbst, Brian
- Bhanot, Umesh
- Wells, Daniel K.
- Grbovic-Huezo, Olivera
- Attiyeh, Marc
- Medina, Benjamin
- Zappasodi, Roberta
- Riaz, Nadeem
- Smoragiewicz, Martin
- Gönen, Mithat
- Levine, Arnold J.
- Fearon, Douglas T.
- Gnjatic, Sacha
- Wolchok, Jedd D.
- DeMatteo, Ronald P.
- Chan, Timothy A.
- Greenbaum, Benjamin D.
- Merghoub, Taha
- Leach, Steven D.
- Venue
- Nature
- Published
- 2017-11
- Volume
- 551
- Issue
- 7681
- Pages
- 512-516
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6145146
- OpenAlex
- W2767699537
- Cited by
- 1,191
- References
- 28
- Citations by year
- 2026: 89 · 2025: 114 · 2024: 119 · 2023: 178 · 2022: 169 · 2021: 153 · 2020: 135 · 2019: 132 · 2018: 94 · 2017: 6
- FWCI
- 44.60
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
- Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (23526, 17263, 15678)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Agence Nationale de la Recherche (ANR-18-CE14-0005)
- National Institutes of Health
- National Cancer Institute (P01CA087497, P30-CA-08748, R01CA190400, P30CA008748, T32CA009501, K12CA184746)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097087)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- pancreatic ductal adenocarcinoma, long-term survival, neoantigens, CA125, CD8+ T cells, T cell immunity, immunogenicity, mutational burden, immune evasion
- MeSH terms
- Cancer Survivors, Exome Sequencing, Adenocarcinoma, Antigens, Neoplasm, Bacterial Proteins, Computer Simulation, Cross Reactions, Humans, Immunotherapy, Membrane Proteins, Pancreatic Neoplasms, Prognosis, T-Lymphocytes, Cytotoxic, Survival Analysis, CA-125 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.